TrialAgain not a word on the 6 trial that are in process, it is like this is not important, R&D not a word either, cost saving, expense reduction and sale reduction that is important for Mr Pidduck., i would have expect at least an increase in revenue, no less revenue this quarter . Path to profitability easy to say not easy to achive , give us a specific target Mr Pidduck then it becomes a real target. Actually it seems that Medipharm is always waiting after someone else for his success.